Efficacy of Sitagliptin Versus Glimepiride 1-3 mg for Treatment of Type-2 Diabetes Patients
| Autor: | Bhaskar Joshi, Annabathini Geetha Bhavani, Praveen Yadav |
|---|---|
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | International Journal of Pharmaceutical Investigation. 10:590-593 |
| ISSN: | 2230-9713 2230-973X |
| Popis: | Objectives: This study is to compare the effect of Sitagliptin and Glimepiride 1-3mg as a combination therapy for type-2 diabetes mellitus patient’s treatment. It is also concern to evaluate the effect of low dosage on type-2 diabetes mellitus patients as an antidiabetic drug. Methods: The type-2 diabetes patient’s clinical data was analyzed during the treatment through the inclusion and exclusion selection methods. The samples of Sitagliptin (1-3 mg) as add on therapy were chosen by open-label study by randomization on type-2 diabetes mellitus. The total 45 patients (n=45) with age group between 20-60 years was received for statistical analysis. The samples are screened by inclusion with the baseline of HbA1c was ≥7.0 % and ≤ 10.5 % was selected. The exclusion criteria are restricted to upper age limit of 60 years and having the symptoms of chronic kidney, hepatic, malignancy. Results: The data of combination therapy is compared with initial data and after 14 weeks of treatment data is considered for the effect of antidiabetic drugs. The statistic results show with greater improvement in HbA1c value and total daily dose of insulin were achieved with Sitagliptin compared to Glimepiride therapy. Conclusion: Finally, Sitagliptin 100mg is an add-on to Metformin treatment shows more adequate results with better tolerance on type-2 diabetes with satisfactory glycemic control is found to be significant reduction with daily dose of insulin in the body. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|